Gyre Therapeutics (NASDAQ:GYRE) Announces Earnings Results

Gyre Therapeutics (NASDAQ:GYRE) released its quarterly earnings data on Friday. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.04), FiscalAI reports. Gyre Therapeutics had a positive return on equity of 3.13% and a negative net margin of 5.44%.The company had revenue of $29.11 million for the quarter, compared to the consensus estimate of $26.49 million.

Gyre Therapeutics Trading Up 4.2%

Gyre Therapeutics stock traded up $0.27 during trading on Friday, hitting $6.67. 67,603 shares of the company were exchanged, compared to its average volume of 52,226. The company has a market capitalization of $743.64 million, a P/E ratio of -74.10 and a beta of 1.92. The business’s 50 day moving average is $6.25 and its 200 day moving average is $7.07. Gyre Therapeutics has a 52 week low of $5.44 and a 52 week high of $9.42.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on GYRE shares. Weiss Ratings cut Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Zacks Research raised Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Wall Street Zen cut Gyre Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $17.00.

Insiders Place Their Bets

In other Gyre Therapeutics news, COO Weiguo Ye sold 12,820 shares of Gyre Therapeutics stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $6.15, for a total transaction of $78,843.00. Following the transaction, the chief operating officer directly owned 700,000 shares of the company’s stock, valued at $4,305,000. The trade was a 1.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 9.50% of the company’s stock.

Institutional Trading of Gyre Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE lifted its position in shares of Gyre Therapeutics by 28.8% during the second quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock valued at $46,000 after purchasing an additional 1,402 shares in the last quarter. JPMorgan Chase & Co. grew its position in Gyre Therapeutics by 84.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after purchasing an additional 2,961 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Gyre Therapeutics by 77.8% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock valued at $54,000 after buying an additional 3,244 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in Gyre Therapeutics in the 4th quarter valued at about $77,000. Finally, Wells Fargo & Company MN increased its stake in Gyre Therapeutics by 132.4% in the 4th quarter. Wells Fargo & Company MN now owns 12,919 shares of the company’s stock valued at $91,000 after buying an additional 7,361 shares during the last quarter. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.